CFDE Data Portal | Search LOC100419928

	Label	Description
	LOC100419928 Gene (Entity type)	ENSG00000255836 - M-phase phosphoprotein 8 pseudogene
	GSE216043 cisplatin 11 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE216043 cisplatin 7 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE80098 GSE80366 progesterone 0 v 8 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE121425 GSE121426 LSD1 inhibition SET-2 2 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE173483 nutlin-3 U2OS 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE146982 metformin 4 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE252944 AKT inhibition 11 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE149768 hypoxanthine 3 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE216043 cisplatin 11 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS

LOC100419928

ENSG00000255836 - M-phase phosphoprotein 8 pseudogene

GSE216043 cisplatin 11 v 2 human dn

A Gene Set from LINCS

GSE216043 cisplatin 7 v 0 human dn

A Gene Set from LINCS

GSE80098 GSE80366 progesterone 0 v 8 human up

A Gene Set from LINCS

GSE121425 GSE121426 LSD1 inhibition SET-2 2 v 0 human dn

A Gene Set from LINCS

GSE173483 nutlin-3 U2OS 1 v 0 human dn

A Gene Set from LINCS

GSE146982 metformin 4 v 5 human dn

A Gene Set from LINCS

GSE252944 AKT inhibition 11 v 0 human up

A Gene Set from LINCS

GSE149768 hypoxanthine 3 v 1 human up

A Gene Set from LINCS

GSE216043 cisplatin 11 v 1 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.